| Unknown | MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer NCT05960630 | Royal Surrey County Hospital NHS Foundation Trust | N/A |
| Recruiting | Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O) NCT05752448 | Baylor College of Medicine | N/A |
| Active Not Recruiting | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian NCT05257408 | Corcept Therapeutics | Phase 3 |
| Unknown | Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of O NCT05059782 | Xi'an Jiaotong University | N/A |
| Active Not Recruiting | Impact of Specific Monitoring of Intraoperative Analgesia Under General Anesthesia on Chronic Pain After Ovari NCT04906187 | Institut Bergonié | N/A |
| Completed | Feasibility Study of a 4 Stage Bowel Obstruction Cancer Diet NCT04898842 | Royal Surrey County Hospital NHS Foundation Trust | N/A |
| Active Not Recruiting | Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies NCT04561362 | BicycleTx Limited | Phase 1 / Phase 2 |
| Completed | Survival Data and Characteristics of Finisterian Patients Treated With PARP Inhibitors for Ovarian Cancer Betw NCT04573933 | University Hospital, Brest | — |
| Unknown | Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival NCT04402333 | Royal Surrey County Hospital NHS Foundation Trust | — |
| Completed | Supportive Programs for Supporting Optimal Recovery in Participants Undergoing Gynecological Surgery NCT03681405 | Wake Forest University Health Sciences | N/A |
| Completed | Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurren NCT05751629 | Tesaro, Inc. | Phase 2 |
| Completed | Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer NCT03562897 | Catalysis SL | Phase 2 |
| Completed | COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. NCT03667716 | Compugen Ltd | Phase 1 |
| Completed | EHealth Mindful Movement and Breathing in Improving Outcomes in Participants Undergoing Gynecologic Surgery NCT03379376 | Wake Forest University Health Sciences | N/A |
| Completed | Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types NCT03012620 | UNICANCER | Phase 2 |
| Unknown | Fluid Balance During Surgery for Ovarian Cancer NCT03006939 | University Hospital, Bonn | — |
| Unknown | HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life NCT03000192 | University Hospital Southampton NHS Foundation Trust | — |
| Completed | Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel NCT01821833 | New Mexico Cancer Research Alliance | N/A |
| Completed | Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum NCT05512676 | Oslo University Hospital | — |
| Recruiting | Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host NCT02732860 | University Health Network, Toronto | — |
| Completed | Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mas NCT02520115 | Barbara Ann Karmanos Cancer Institute | Phase 1 |
| Terminated | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnos NCT02470585 | AbbVie | Phase 3 |
| Completed | Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer NCT01896778 | Roswell Park Cancer Institute | N/A |
| Completed | [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer NCT01608009 | Imperial College London | Phase 1 |
| Completed | Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors NCT01929720 | Ohio State University Comprehensive Cancer Center | N/A |
| Terminated | Family Communication of Hereditary Breast and Ovarian Cancer Risk Among African Americans NCT01374685 | National Human Genome Research Institute (NHGRI) | — |
| Withdrawn | Prediction of Ovarian Malignancy in the Presence of Sonographic Pelvic Mass NCT01477788 | HaEmek Medical Center, Israel | — |
| Completed | Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer NCT01139957 | Gynecologic Oncology Group | — |
| Completed | Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovaria NCT00494442 | AstraZeneca | Phase 2 |
| Completed | Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer NCT00436215 | National Cancer Institute (NCI) | Phase 2 |
| Completed | DOXIL for Consolidation Therapy in Ovarian Cancer. NCT00248248 | Southeastern Gynecologic Oncology | Phase 2 |
| Completed | Phase II CT-2103/Carboplatin in Ovarian Cancer NCT00069901 | CTI BioPharma | Phase 2 |
| Completed | Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 NCT00034281 | Takeda | Phase 1 |
| Completed | A Pilot Study of a Protein Profile Test in Ovarian Cancer Patients in Remission to See if Protein Changes Can NCT00001938 | National Cancer Institute (NCI) | — |
| Terminated | p53 Vaccine for Ovarian Cancer NCT00001827 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Microarray Analysis for Human Genetic Disease NCT00001898 | National Human Genome Research Institute (NHGRI) | — |
| Completed | A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With N NCT00001426 | National Cancer Institute (NCI) | Phase 2 |